GLP-1 Evidence

Mediċina

Semaglutide: x'juru t-testi

Semaglutide f'2.4 mg kull ġimgħa pproduċa madwar 15% tnaqqis medju fil-piż tal-ġisem matul 68 ġimgħa. Dak in-numru huwa reali, riprodott, u spiss misinterpretat.

Aġġornat 3 min read 32 ċitazzjonijiet Saħħa tal-evidenza 5/5

Tableti rotondi ħfief stampati b'kodifikazzjoni identifikattiva, imħarsa minn fuq
Larry D. Moore · CC BY 4.0 · Wikimedia Commons

It-titolu tat-testa

STEP 1 randomizzat adulti b'overweight jew obeżità u mingħajr dijabete għal semaglutide 2.4 mg kull ġimgħa jew placebo, it-tnejn bi intervent ta' stil ta' ħajja, għal 68 ġimgħa [9]. It-tibdil medju fil-piż kien madwar −14.9% fuq il-mediċina kontra −2.4% fuq placebo. Madwar terz tal-parteċipanti fuq il-mediċina tilfu 20% jew aktar mill-piż tal-ġisem — riżultat li qabel kien il-provinċja tas-surgija bariatrika.

Żewġ affarijiet huma ta' valur li żżomm. L-ewwel, dak huwa medju: id-distribuzzjoni hija wiesgħa, u minoranza sostanzjali tilfu ftit ħafna. It-tieni, l-arm ta' placebo rċeviet ukoll konsulenza ta' stil ta' ħajja, għalhekk il-2.4% mhix "ma tagħmilx xejn" — l-effett tal-mediċina huwa mkejjel fuq il-konsulenza li nnifisha tagħmel xi ħaġa.

In-numru huwa iżgħar jekk għandek dijabete

STEP 2 wettaq l-istess disinn f'adulti b'dijabete tat-tip 2 u sab madwar 9.6% tnaqqis fil-piż fl-istess doża [8]. Dak il-fossa bejn madwar 15% u madwar 10% jidher ripetutament madwar il-klassi u mhuwiex speċifiku għal semaglutide. Meta-analiżi komparattiva madwar GLP-1 agonists turi l-istess mudell fuq it-tnaqqis fil-piż u l-punti ta' glycaemic [3].

Semaglutide 2.4 mg kull ġimgħa — tibdil medju fil-piż skont il-popolazzjoni
ProvaPopolazzjoniDaqsTibdil medju fil-piżPlacebo
STEP 1 [9]Obeżità, mingħajr dijabete68 ġimgħa≈ −14.9%≈ −2.4%
STEP 2 [8]Obeżità + dijabete tat-tip 268 ġimgħa≈ −9.6%≈ −3.4%
STEP 4 [7]Kontinwazzjoni kontra rtirar wara 20 ġimgħa48 ġimgħa oħraKontinwazzjoni: tnaqqis ieħorRtira: riġenerazzjoni
SELECT [5]Obeżità + mard kardjovaskulari~4 sninSostenut ≈ −10%≈ −1.5%

Kemm żmien jibqa' jaħdem?

Iktar minn dak li s-snin ta' 68 ġimgħa juru. Meta-analiżi tad-dejta fit-tul sabet li l-effett jibqa' sostenut ħafna lil hinn minn sena [1], u t-testa kardjovaskulari SELECT — li għamlet madwar erba' snin u ma kienx iddisinjat bħala prova ta' piż — wera li t-tnaqqis fil-piż jippjanċa madwar 10% u mbagħad jibqa', minflok jiddgħajjef [5]. Il-pjanċa hija reali; ir-reversjoni li l-kriti predixxew mhix, sakemm it-trattament ikompli.

Tnaqqis sostenut fil-piż fuq trattament kontinwu

Semaglutide kontra tirzepatide

Għall-dijabete tat-tip 2, SURPASS-2 komparat tirzepatide kontra semaglutide 1 mg u favur tirzepatide. Għall-obeżità speċifikament, il-komparazzjoni diretta fil-dożi ta' obeżità ġiet aktar tard u kienet deċiżiva: tirzepatide pproduċa tnaqqis medju fil-piż ħafna akbar minn semaglutide [10], konsistenti mal-komparazzjonijiet reali u indiretti preċedenti [11].

Dan ma jagħmilx awtomatikament lil tirzepatide l-għażla t-tajba għal individwu — it-tolleranza, il-prezz, l-iskorta u l-kumorbiditajiet kollha għandhom influwenza fuqha — iżda fuq it-tnaqqis fil-piż waħdu l-ordni mhix fil-kontrovers. Ara tirzepatide.

Fejn semaglutide għandu gwida warajh

Minbarra t-tnaqqis fil-piż, semaglutide għamel pass 'il quddiem fil-gwida formali għall-mard assoċjat ma' steatosi tal-liver assoċjat ma' disfunzjoni metabolika, fejn il-linji gwida Ewropej konġunti jaddressaw ir-rwol tiegħu [2]. Huwa wkoll l-unika agent fil-klassi li għandu prova ta' riżultat kardjovaskulari kompluta f'popolazzjoni obeża mingħajr dijabete [5], li hija koperta fuq il-paġna kardjovaskulari.

Bank ta' laboratorju tal-kimika bi fliexken tal-ħġieġ u boroż ta' reattivi f'pożizzjoni
Cjp24 · CC BY-SA 3.0 · Wikimedia Commons

Mistoqsijiet komuni

Huwa Wegovy differenti minn Ozempic?
L-istess molekula, doża u indikazzjoni differenti. It-testi tal-obeżità użaw 2.4 mg kull ġimgħa; id-dożi tad-dijabete huma aktar baxxi. Id-daqs tal-effett imsemmi għat-tnaqqis fil-piż jiġi mill-ogħla doża.
Għaliex tlift inqas minn 15%?
Għax 15% huwa medju. Ir-rispons jvarja ħafna bejn individwi f'kull prova, u n-nies b'dijabete tat-tip 2 tilfu madwar terz inqas b'mod medju [8].
Jekk tieqaf taħdem wara ftit xhur?
Le. It-tnaqqis fil-piż jmur bil-mod u jippjanċa, tipikament matul is-sena t-tieni, iżda d-dejta fit-tul turi li t-tnaqqis huwa mantenut fuq trattament kontinwu [1][5].
Nista' nieħuha biss biex nitilfu ftit kilogrammi u mbagħad nieqaf?
Tista', iżda aspettati li l-maġġoranza tat-tnaqqis terġa' lura. Dak huwa l-findings konsistenti tad-dejta ta' rtirar [6][7] u huwa diskuss fil-fond fuq il-paġna ta' waqfien.
Il-provi li hemm wara din il-paġna Bar imwaħħal li juri l-kompożizzjoni tal-12 pubblikazzjoni ċċitata f'din il-paġna skont it-tip ta' studju. 4101meta-analysis (4)randomised trial (10)other (1)
11 pubblikazzjonijiet, 2021–2025. Dan huwa miks li fih kemm provi kif ukoll sintesi, li huwa l-pożizzjoni minn fejn talba dwar il-kawża hija raġonevoli. Sors: il-lista ta' ċitazzjonijiet ta' din il-paġna, hawn taħt.

Referenzi

Kull ċitazzjoni hawn taħt tgħaqqad mal-record oriġinali peer-reviewed fuq PubMed jew permezz ta' DOI. Xejn hawnhekk m'għandux ikun sostitut għal parir mediku.

  1. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  2. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  3. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Moiz A, Levett JY, Filion KB, et al. · The American journal of cardiology · 2024 · Meta-analysis DOIPubMed 38679221
  4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOIPubMed 38851997
  5. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  6. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOIPubMed 38286487Full text
  7. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review Feier CVI, Vonica RC, Faur AM, et al. · International journal of molecular sciences · 2024 · Systematic review DOIPubMed 38673931Full text
  8. Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis He K, Guo Q, Zhang H, et al. · Diabetes, obesity & metabolism · 2022 · Meta-analysis DOIPubMed 34866313
  9. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  10. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial Wharton S, Freitas P, Hjelmesæth J, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40961952
  11. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity Wharton S, Lingvay I, Bogdanski P, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40934115
  12. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity Garvey WT, Blüher M, Osorto Contreras CK, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544433
  13. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Davies MJ, Bajaj HS, Broholm C, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544432
  14. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease Cummings JL, Atri A, Feldman HH, et al. · Alzheimer's research & therapy · 2025 · Randomised controlled trial DOIPubMed 39780249Full text
  15. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  16. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  17. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  18. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial Colhoun HM, Lingvay I, Brown PM, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38796653Full text
  19. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  20. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  21. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  22. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  23. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  24. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33625476Full text
  25. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  26. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Davies M, Færch L, Jeppesen OK, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 33667417
  27. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  28. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  29. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial Pratley RE, Aroda VR, Lingvay I, et al. · The lancet. Diabetes & endocrinology · 2018 · Randomised controlled trial DOIPubMed 29397376
  30. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  31. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025 · Clinical trial DOIPubMed 40353578
  32. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 · Journal article DOIPubMed 38976257Full text

Din il-paġna ġiet tradotta awtomatikament mill-Ingliż. Il-citazzjonijiet u n-numri mhumiex mibdula. Aqra l-original Ingliż jekk xi ħaġa taqra b'mod stramb. Aqra l-original Ingliż